FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour By Ogkologos - April 4, 2025 693 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MOTION study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR FDA Approval of KRAS Inhibitor Sotorasib for Lung Cancer Hailed as... June 25, 2021 Opinion: What should the cancer agenda look like for the new... September 22, 2022 What Happens If More People Get Screened for Cancer? January 26, 2024 Leading Change in Cancer Clinical Research, Because Our Patients Can’t Wait May 31, 2024 Load more HOT NEWS Doctors Worry Breast Cancer Cases Are Being Missed as Mammogram Rates... 12-Yr-Old Chokes Up When Nurses Surprise Him With Special Song For... Liquid Biopsies on the Horizon for Children with Solid Cancers Encorafenib, Cetuximab Combination Approved for Metastatic Colorectal Cancer
